Stocktoria

Taysha Gene Therapies, Inc. TSHA

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-09-24

Taysha Gene Therapies, Inc. statistics & valuation

Market cap$1.8B
P / B7.4×
Net margin-1115.3%
Return on equity-44.1%
FCF margin-960.1%
Net cash$269.7M
Enterprise value USD$1.6B
Earnings yield EBIT/EV-7.1%
Return on capital-34.9%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-6635.30% -722.10% -1071.60% -1115.30% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-6492.70% -468.80% -1097.60% -1130.60% 202020212022202320242025
Return on equity (%)
-23.90% -183.00% -17493.60% -148.90% -124.80% -44.10% 202020212022202320242025
Shares outstanding
37.8M 38.5M 63.2M 187.0M 250.1M 319.7M 202020212022202320242025
Net debt ($)
-$111.9M -$49.9M -$103.4M -$95.1M -$269.7M 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-23.20% -81.60% -131.50% -64.60% -55.70% -31.70% 202020212022202320242025
Free cash flow margin (%)
-4356.90% -497.60% -979.20% -960.10% 202020212022202320242025
Debt / equity (×)
0.39× 40.01× 0.54× 0.61× 0.20× 202020212022202320242025
EPS ($)
-$4.64 -$3.78 -$0.96 -$0.36 -$0.34 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-1130.6%-1097.6%-468.8%-6492.7%——
Net margin-1115.3%-1071.6%-722.1%-6635.3%——
FCF margin-960.1%-979.2%-497.6%-4356.9%——
Return on assets-31.7%-55.7%-64.6%-131.5%-81.6%-23.2%
Return on equity-44.1%-124.8%-148.9%-17493.6%-183.0%-23.9%
Debt / equity0.20×0.61×0.54×40.01×0.39×—
Current ratio12.235.424.081.543.0836.17

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.